Novartis’ troubles over the Zolgensma data manipulation incident show no sign of lessening. The company is on the defensive again after it emerged a senior manager sold almost $1 million worth ...

The pharmaceutical company says it will continue to operate its production facility near Research Triangle Park.

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

Since 2020, the global SMA treatment landscape has progressed, with three treatments now approved, according to Novartis. Along with Zolgensma – which made its debut in 2019 – Biogen has had ...

In a statement to ProPublica, Novartis said Zolgensma’s price reflects its benefits to children with SMA and to society more broadly. “Zolgensma is consistently priced based on the value it ...

Zolgensma is a prescription drug that’s used to treat spinal muscular atrophy (SMA) in young children. Zolgensma’s cost may depend on factors such as your child’s treatment plan and whether ...

Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Last year, Novartis reported revenue from Zolgensma of $1.2 billion.

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

AveXis, a subsidiary of Novartis, knew about the manipulated data as early as March, two months before it was officially approved. AveXis manufactures the product in question, Zolgensma, which stands ...

The company uses the facility to manufacture its spinal muscular atrophy gene therapy, called Zolgensma. Novartis-owned firm picks Durham over Illinois, Ireland for 200 jobs Multibillion-dollar ...